SupplementaryFile 1

Spanish Society of Rheumatology (SER) criteria for expert participation in REDOSER (Appropriateness criteria for biological therapy dose reduction in immune-mediated arthritis)

Preliminary information about REDOSER was presented at the SER annual meeting in May 2015. The Research Unit of SER then launched an open call to all its members that was available on the SER webpage and was sentby email to all members of the Society. Researchers were informed of deadlines, dates of meetings, and project workload.Applications for involvement in REDOSERaccompanied by a CV were sent from June 2 until June 19, 2015.Candidates stated their preferences for involvement as a member of theWorkingGroup and/or Rating Panel. A total of 22 proposals for the Rating Panel and 21 proposals for the WorkingGroup were received. The CVswere evaluated by the SERResearch Committee according to the following criteria:

1. Experience in treatmentwith or researchonbiological drugs in patients with RA, axSpA, and pSpA.All candidates had to provide full details of their experience.

2. Completion of the specific SERform for Disclosure of Conflicts of Interest,which wasavailable onthe website.

3. As suggested by the experts in the RAND/UCLA Appropriateness Method (PL and AJB), members (rheumatologists) had to be from different regions throughout Spain andwork in hospitals of different levels. At least two panel members had to beunder 40 years old.

After evaluation of CVs and discussion at the SER Research Committee meeting, the composition of the REDOSER membership was as follows:

Principal Investigator

Isidoro González Álvaro, MD, PhD (HU La Princesa, Madrid).

WorkingGroup

Alejandro Balsa Criado, MD, PhD (HU La Paz, Madrid).

Rosario García Vicuña, MD, PhD (HU La Princesa, Madrid).

Isidoro González Álvaro, MD, PhD (HU La Princesa, Madrid).

Raimon Sanmartí Sala, MD, PhD (H Clinic, Barcelona).

Jesús Sanz Sanz, MD (HU Puerta de Hierro, Majadahonda, Madrid).

Rating Panel

Raquel Almodóvar González, MD (HU Fundación Alcorcón, Alcorcón, Madrid).

Javier Bachiller Corral, MD (HU Ramón y Cajal, Madrid).

Rafael Cáliz Cáliz, MD, PhD (HU Virgen de las Nieves, Granada).

Gloria Candelas Rodríguez, MD (H Clínico San Carlos, Madrid).

Cristina Fernández Carballido, MD, PhD (H General Universitario de Elda, Alicante).

Ángel María García Aparicio, MD (H Virgen de la Salud, Toledo).

Blanca García Magallón, MD (H General San Jorge, Huesca)

Antonio Gómez Centeno, MD (H ParcTaulí, Sabadell, Barcelona)

Ana Ortiz García, MD, PhD (HU La Princesa, Madrid)

Beatriz Tejera Segura, MD (HU de Canarias, Tenerife)

Rating panel moderator

Pablo Lázaro y de Mercado, MD, PhD, MBA

Literature review group

Ana Ortiz García, MD, PhD (HU La Princesa, Madrid).

Miguel Ángel Abad Hernández, MD (Hospital Virgen del Puerto, Plasencia, Cáceres).

Methodological support (Spanish Society of Rheumatology)

Carlos SánchezPiedra, BPharm, PhD

Methodology support (External)

Pablo Lázaro y de Mercado, MD, PhD, MBA

Antonio Javier Blasco Bravo, PhD, MPH